Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has entered into a securities purchase agreement with a single healthcare-focused institutional inves… Read More

Lexaria’s patented DehydraTECH(TM)-processed CBD has shown its ability to lower blood pressure in patients over multiple weeks This technology has also shown positive impacts… Read More

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its intention to launch new human and animal studies to examine DehydraTECH(TM)-proce… Read More

Mit DehydraTECH verarbeitete GLP-1-Arzneimittel werden im Hinblick auf folgende potenzielle Verbesserungen bewertet: – weniger Nebenwirkungen; – höherer Gewichtsverlust; &n… Read More

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the incorporation of a new wholly owned subsidiary under the name Lexaria Nutraceut… Read More

Lexaria’s IND application for its U.S. Phase 1b Hypertension Clinical Study, HYPER-H23-1, remains on track despite setbacks Work mostly under Lexaria’s control was compl… Read More

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently celebrated the receipt of U.S. patent #11,700,875, titled “Compositions and Methods For… Read More

The ADA reports that 37.3 million Americans had diabetes in 2019, and the number has been growing by an average 1.4 million each year 95% of Americans with diabetes are diagnosed wi… Read More

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today provided an update on the status of its anticipated submission of an Investigational New Drug (… Read More

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that its groundbreaking research utilizing its patented DehydraTECH(TM)-processed c… Read More

Lexaria’s NIC-H22-1 study proved that its patented DehydraTECH(TM)-nicotine tobacco-free pouch was statistically significantly faster-acting than alternatives The study, which… Read More

Lexaria’s human oral nicotine study, NIC-H22-1, comparing world-leading brands and the company’s DehydraTECH(TM)-Nicotine tobacco-free pouch, reported positive results, includi… Read More

Lexaria’s patented DehydraTECH(TM)-CBD achieved promising results for diabetes control and weight loss in animals during the pre-clinical animal study DIAB-A22-1 The weight lo… Read More

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting results from its 2023 human oral nicotine study NIC-H22-1. The study compared Lexaria&rs… Read More

Lexaria recently celebrated the receipt of its 35th overall granted patent worldwide when the USPTO recently awarded US patent #11,700,875, titled “Compositions and Methods For Subli… Read More

Lexaria Nutraceutical Corp. will keep Lexaria’s overall strategy of maximizing the company’s patented DehydraTECH(TM) technology in various markets, excluding pharmaceutical… Read More

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today reported its intention to conduct a human clinical study to examine DehydraTECH-CBD for purpose… Read More

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has incorporated a new wholly owned subsidiary: Lexaria Nutraceutical Corp., or LEXX Nutra. According to the… Read More

Lexaria’s new patent includes claims for many types of nicotine, including nicotine benzoate, nicotine ditartrate, nicotine citrate, nicotine polacrilex, and many others, for use in… Read More

Lexaria’s patented DehydraTECH(TM) technology enhances the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats… Read More

The article covers the concentration of cannabidiol in hypertensive women and men using the company’s patented DehydraTECH(TM)-processed CBD The global cardiovascular drugs… Read More

Lexaria is a global innovator in drug delivery platforms with an expanding portfolio of patents that currently stands at 34 granted patents and many patents pending worldwide These… Read More

The bioavailability enhancement technologies and services market is expected to reach $10 billion by 2035, growing at a CAGR of approximately 11% Drug developers are shifting focus… Read More

Lexaria just released its mid-year update, highlighting its key milestones so far and its objectives going forward, summarized in a recent Zacks update Of note was the company&rsquo… Read More

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently completed its animal study HOR-A22-1, which showed that the company’s patented DehydraT… Read More

Lexaria’s latest peer-reviewed publications were published in June 2023 in the International Journal of Molecular Sciences, Advances in Therapy, and Biomedicine & Pharmacotherapy… Read More

Lexaria Bioscience recently received four new patents granted in Canada and the United States In the U.S., the company received two new hypertension-related patents expected to be o… Read More

Diabetes – Blood glucose levels reduced by 19.9% with patented DehydraTECH(TM) processed CBD Epilepsy – Lower dosages of DehydraTECH-CBD were needed to achieve the same… Read More

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of four newly granted patents. The company secured two new Canadian paten… Read More

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is releasing additional findings from its DIAB-A22-1 study, a diabetes animal study designed to evaluate the… Read More

In May, Lexaria made a number of positive announcements related to its R&D initiatives In addition to holding its 2023 Annual Meeting, the company completed dosing for its human… Read More

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the appointment of a new chief financial officer. Effective immediately, Mike Shankma… Read More

Lexaria just announced additional findings from its HYPER-H21-4 human clinical study, highlighting significant reductions in several pro-inflammatory biomarkers associated with cardiovascu… Read More

Lexaria just announced the completion of batch manufacturing of its patented DehydraTECH(TM)-processed CBD and placebo materials for its FDA Phase 1b HYPER-H23-1 human clinical study… Read More

Lexaria held its virtual 2023 Annual Shareholders meeting on May 9, 2023 On the agenda were the election of six director nominees, the ratification of the appointment of the company… Read More

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced additional findings from last year’s human clinical study HYPER-H21-4. The find… Read More

Lexaria recently reported that dosing of the targeted 36 volunteers in its human clinical oral nicotine study, NIC-H22-1, had been completed The company hopes to demonstrate that it… Read More

Lexaria’s patented DehydraTECH(TM) technology enhances drug bioavailability, making it useful for a wide range of product formats, including pharmaceuticals, neutraceuticals, consume… Read More

Lexaria just awarded InClin, Inc. the contract for CRO services, in a move that lines up with the company’s upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1… Read More

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced the closing of its public offering of 2,106,000 units, with each consisting of one shar… Read More

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the results of the 2023 Annual Meeting. According to the update, the company held the… Read More

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has completed dosing for 36 subjects in its human clinical oral nicotine study: NIC-H22-1. According to the… Read More

Zacks recently released a research report covering Lexaria Bioscience, a global innovator in drug delivery platforms The report discusses the company’s ongoing research and de… Read More

Lexaria recently completed its diabetes animal model study, DIAB-A22-1, an ambitious study that explored the potential of its patented DehydraTECH(TM)-processed cannabidiol (“CBD&rdq… Read More

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it awarded the contract for clinical research organization (“CRO”) s… Read More

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has received notifications of four new patents either awarded or allowed. In… Read More

Chris Bunka, Lexaria’s CEO, has reiterated the company’s commitment to creating value for its shareholders with the licensed use of its patented DehydraTECH(TM) technology… Read More

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is increasing the bioavailability of and improving the way that active pharmaceutical ingredients (&ld… Read More

DehydraTECH(TM)-enabled drugs and product formats improve the speed of onset, increase bioavailability, increase brain absorption, enhance drug potency, reduce drug administration costs, a… Read More

Lexaria Bioscience, a global innovator in drug delivery platforms, has developed and patented the DehydraTECH(TM) drug delivery platform technology The company has undertaken multip… Read More

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is positioned for opportunity with its patented DehydraTECH(TM) technology and its wide-reaching poten… Read More

Research Nester published a report titled “Medical Marijuana Market: Global Demand Analysis & Opportunity Outlook 2028″ which delivers a detailed overview of the me… Read More

Toronto, Ontario--(Newsfile Corp. - December 19, 2022) - Hill Street Beverage Company Inc. (TSXV: HILL) (OTC Pink: HSEEF) ("Hill Street" or the "Company"), a progressive bioscience implemen… Read More

DUBLIN–(BUSINESS WIRE)–The “North America Legal Marijuana Market Size, Share & Trends Analysis Report, by Product Type (Flower), by Marijuana Type (Adult), by Medical U… Read More

Lexaria Bioscience Pursuing Regulatory Approvals for DehydraTECH CBD Lexaria Bioscience Corp. (NASDAQ: LEXX) is embarking on new programs as well as extending ongoing ones as it pursues… Read More